Login / Signup

Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors.

Takashi KawaharaKoji KawaiTakahiro KojimaYoshiyuki NagumoShotarou SakkaSyuya KandoriHiromitsu NegoroBryan J MathisKazushi MaruoKoji MiuraNoriaki SakamotoNobuo ShinoharaShinichi YamashitaKan YonemoriTakeshi KishidaOsamu UkimuraKazuo NishimuraYasuyuki KobayashiHiroyuki Nishiyama
Published in: International journal of urology : official journal of the Japanese Urological Association (2022)
Tumor mutation burden is a potential biomarker for future testing of germ cell tumor response.
Keyphrases
  • germ cell
  • open label
  • combination therapy
  • photodynamic therapy
  • risk factors
  • placebo controlled